Research Funding

The Lewy Body Dementia Association (LBDA) New Investigator Pilot Study Award is intended to support young investigators and new investigators in Lewy body dementias (LBD) who have not yet received an R01 award from the National Institutes of Health, to gather preliminary data for projects proposed in future LBD grant applications.

LBDA is seeking proposals for translational or clinical research studies using human subjects, biofluid/tissue samples, or existing clinical data sets to answer questions about LBD diagnosis, clinical management, and well-being of persons with LBD and family caregivers. Basic science applications will not be accepted.

Full details are available on the Request for Proposals.

The purpose of the NINDS Alzheimer’s Disease and Alzheimer’s Disease-Related Dementias (AD/ADRD) Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to support a cohort of new and talented, independent investigators from diverse backgrounds conducting AD/ADRD research. The program is designed to facilitate a timely transition of eligible postdoctoral researchers from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees establish independent research programs in the AD/ADRD field.

The purpose of this Funding Opportunity Announcement (FOA) is to solicit studies that will advance the mechanistic understanding of small vessel vascular contributions to cognitive impairment and dementia (VCID) through the development of new technologies and innovative methods that enable the imaging and/or functional assessment of the small blood and lymphatic vessels and perivascular spaces of the brain.

This program aims to facilitate the development of tools and technology to image, profile and/or mechanistically characterize CNS small blood and lymphatic vessels in Alzheimer’s Disease and Alzheimer’s Disease-Related Dementia (AD/ADRD) animal models or patient populations. The overall goal is to use such technologies or methods to elucidate the mechanisms that link CNS small blood and lymphatic vessel dysfunction to dementia outcomes in the AD/ADRDs, their potential role in repair processes, and their response to therapies. Preclinical studies of small vessel VCID in vitro and/or animal models and pilot human subject studies (that do not meet the NIH definition of clinical trial) are appropriate for this FOA.

The goal of this Notice of Special Interest (NOSI) is to encourage the use of existing cohorts and datasets for well-focused secondary analyses to investigate novel scientific ideas and/or address clinically related issues on: (1) aging changes influencing health across the lifespan (e.g., Alzheimer’s disease and Alzheimer's disease-related dementias (AD/ADRD)), (2) diseases and disabilities in older persons, and/or (3) the changes in basic biology of aging that underlie these impacts on health (the hallmarks of aging). Activities of high priority include those addressing specific hypotheses in basic biological research, clinical aging research, behavioral or social research, and/or translational geroscience to inform: the design and implementation of future epidemiologic or human intervention studies; interventions in animal models of aging; research on behavioral and social factors over the life course that influence health (e.g., early life adversity); current geriatric practice in maintenance of health, disease management, and prevention of disability; or research testing of possible causal relationships between rates of aging and findings extracted by secondary analysis of the existing data. Existing datasets may also be used to develop and test new mathematical modeling and statistical analytical approaches. Analyses of sex and/or gender differences across health disparity groups (e.g., racial and ethnic groups, socioeconomic status, and sexual and gender minorities) are of high relevance. Use of cohorts that are linked to electronic health record systems and/or Centers for Medicare and Medicaid Services (CMS) administrative data are especially welcome.

Recent findings have raised the hypothesis that systemic immune responses could play direct or indirect roles in brain neurodegeneration leading to AD/ADRD and have been significantly less studied than immune responses confined exclusively to within the brain parenchyma. The purpose of this funding opportunity announcement (FOA) is to support partnerships and new collaborations between neuroscientists and immunologists to expand the research base in this area with the long-term goal of bringing more immunology expertise into the AD/ADRD field and to support further work in this area through investigator-initiated and other mechanisms.

This Funding Opportunity Announcement (FOA) will support pragmatic trials within Stage IV of the NIH Stage Model to improve dementia care across multiple dementia care settings that will: (1) be designed to address practical comparative questions faced by Alzheimer’s disease (AD) and AD-related dementia (ADRD) patients, clinicians, and caregivers (both paid and unpaid); (2) include broad and diverse populations; and (3) be conducted in real-world settings with adequate sample size. These trials are intended to produce results that can be directly adopted by healthcare providers, patients, or caregivers for rapid dissemination and implementation. Successful applications will: (1) improve quality of care of persons with dementia; (2) improve quality of life for persons with dementia and their informal caregivers; (3) deliver more patient-focused, cost-effective care across multiple settings; and/or (4) reduce disparities in dementia care.

This FOA will support Stage I or Stage III pilot research to test the feasibility of implementing and integrating interventions (R61 phase) that, if successful, can transition to an R33 phase (Stage IV) for implementation of large pragmatic trials.

The transition from the R61 to the R33 phase of the award will be administratively reviewed and determined by successful completion of the go/no-go criteria that are specified for the R61 phase.

This Funding Opportunity Announcement (FOA) solicits mechanism-focused dementia care and caregiver support intervention development research at Stages I through V of the NIH Stage Model to address the care needs and promote the health, function, and well-being of persons with Alzheimer’s disease (AD) and Alzheimer’s disease-related dementias (ADRD) and of those providing their care. The NIH Stage Model offers a framework to: (1) support development of efficacious interventions that are defined by their principles; and (2) ensure that these efficacious interventions can be administered in the community or in health systems with fidelity to the intervention’s principles. This includes the development, testing, and validation of scalable training materials and procedures so that these interventions can be delivered with fidelity in community settings or health systems. Settings can include the home, community, or formal care settings, such as nursing homes, assisted living facilities, nursing and rehabilitation centers, hospitals, adult day care, and specialized hospice settings. The overarching purpose of this FOA is to help to lay the groundwork for real-world implementation of AD/ADRD care and caregiving interventions.

The purpose of this funding opportunity is to support projects to identify cellular changes in ADRD post-mortem brain tissue across disease progression. Applicants are encouraged to propose single-nucleus transcriptomic and epigenomic studies that identify changes in neuronal, glial, or vascular cells over multiple ADRD stages, from early to mid-stage. All sequencing data and any available pre-mortem clinical data will be broadly shared with the research community.

The purpose of this funding opportunity announcement is to expand the use of existing ADRD data resources to drive, via computational model development and dissemination, new discoveries that can lead to better understanding of mechanisms, clinical risk assessment and outcomes, and to identify novel candidate biomarkers for ADRD.

The purpose of this funding opportunity announcement (FOA) is to support hypothesis-driven clinical research applications that are focused on discovering novel diagnostic, prognostic, and/or therapeutic biomarkers for the Lewy Body Dementias (LBD). Biomarker research must be conducted in patients with LBD, must follow Parkinson's Disease Biomarker Program (PDBP) protocols for clinical assessment and biospecimen collection, and must be broadly shareable through the PDBP repositories.

The objectives of the NIH Academic Leadership Career Award (K07) are to increase the pool of individuals with academic and research expertise in a specific area of biomedical research and to enhance the educational or research capacity at the grantee institution. The K07 Leadership Award provides support for senior investigators who are interested in improving the curricula and enhancing the health-related research capacity within an academic institution.

The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research.

The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research.

The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research.

These CDAs seek to support the development of early-stage MD, PhD, or equivalent researchers who seek careers conducting ePCTs for people living with AD/ADRD and their care partners. The IMPACT Collaboratory prioritizes applications that address dementia care for people of all backgrounds and promote health equity.

The purpose of this Funding Opportunity Announcement (FOA) is to solicit an Alzheimer's disease and Alzheimer's disease related dementias (AD/ADRD)-focused U01 that is ancillary to, but integrated with, the Midlife in the United States Study (MIDUS) U19 (see PAR-21-156) to provide in-depth information to elucidate behavioral, social, psychological and biological pathways of risk and resilience to cognitive decline and AD/ADRD. In addition to capitalizing on already-collected data, new measures should be included to test hypotheses regarding development of AD/ADRD via cumulative stress exposures over 30 prior years of data collection. As well, the research should examine the protective influence of psychosocial resources, affective style, and lifestyle factors assessed over multiple prior waves of MIDUS. The new assessments on two national samples with many years of information on potential influences on AD/ADRD hold potential for yielding invaluable insights relevant for preventative interventions and treatments in future studies.

The purpose of this Funding Opportunity Announcement (FOA) is to solicit an Alzheimer's disease and Alzheimer's disease related dementias (AD/ADRD)-focused U01 that is ancillary to, but integrated with, the Midlife in the United States Study (MIDUS) U19 (see PAR-21-156) to provide in-depth information to elucidate behavioral, social, psychological and biological pathways of risk and resilience to cognitive decline and AD/ADRD. In addition to capitalizing on already-collected data, new measures should be included to test hypotheses regarding development of AD/ADRD via cumulative stress exposures over 30 prior years of data collection. As well, the research should examine the protective influence of psychosocial resources, affective style, and lifestyle factors assessed over multiple prior waves of MIDUS. The new assessments on two national samples with many years of information on potential influences on AD/ADRD hold potential for yielding invaluable insights relevant for preventative interventions and treatments in future studies.

The objective of the NINDS Institutional Research Training Program is to support outstanding training with the breadth and depth to prepare advanced predoctoral and postdoctoral trainees to become successful scientists in a rapidly evolving research enterprise that is increasingly complex and multidisciplinary.

The objective of the NINDS Institutional Research Training Program is to support outstanding training with the breadth and depth to prepare advanced predoctoral and postdoctoral trainees to become successful scientists in a rapidly evolving research enterprise that is increasingly complex and multidisciplinary.

The objective of the NINDS Institutional Research Training Program is to support outstanding training with the breadth and depth to prepare advanced predoctoral and postdoctoral trainees to become successful scientists in a rapidly evolving research enterprise that is increasingly complex and multidisciplinary.

This unique award provides funding and committed project support by a team of pharmaceutical industry experts through a collaboration with the Alzheimer’s Drug Discovery Foundation (ADDF) and Harrington Discovery Institute.

The 2021 ADDF-Harrington Scholar RFP places high priority on targets related to emerging therapeutic areas for dementia, particularly epigenetics and proteostasis. Other novel targets are encouraged, such as neurovascular health, neuroprotection, synaptic activity and neurotransmitters, inflammation, mitochondria and metaboloic function, ApoE, other aging targets. NOTE: This RFP does not support anti-amyloid approaches (e.g. Abeta vaccines, beta- or gamma-secretase inhibitors) or cholinesterase inhibitors.

The ADDF seeks to support studies of cognitive symptoms due to health conditions, comparative effectiveness research, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline.

The ADDF seeks to support studies of cognitive symptoms due to health conditions, comparative effectiveness research, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline.

The ADDF seeks to support studies of cognitive symptoms due to health conditions, comparative effectiveness research, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline.

This Funding Opportunity Announcement (FOA) invites applications to develop and implement Phase Ib to III clinical trials of promising pharmacological and non-pharmacological interventions that may prevent, delay, or treat the symptoms of Alzheimer's disease (AD) and other age-related dementias using the Alzheimer's disease Clinical Trials Consortium (ACTC) trial coordination and management infrastructure.

The aim of this RFP is to further develop and validate established biomarkers for which there is a clear clinical need in Alzheimer's disease and related dementias. This RFP prioritizes biomarkers with a defined context of use, a clear advantage over other relevant biomarkers, and a path to commercialization and/or clinical use.

The aim of this RFP is to further develop and validate established biomarkers for which there is a clear clinical need in Alzheimer's disease and related dementias. This RFP prioritizes biomarkers with a defined context of use, a clear advantage over other relevant biomarkers, and a path to commercialization and/or clinical use.

The aim of this RFP is to further develop and validate established biomarkers for which there is a clear clinical need in Alzheimer's disease and related dementias. This RFP prioritizes biomarkers with a defined context of use, a clear advantage over other relevant biomarkers, and a path to commercialization and/or clinical use.

The PACT RFP supports IND-enabling studies and early-phase clinical trials that test promising pharmacological interventions and devices for Alzheimer’s disease (AD) and related dementias. Both disease-modifying and symptomatic agents will be considered.

The PACT RFP supports IND-enabling studies and early-phase clinical trials that test promising pharmacological interventions and devices for Alzheimer’s disease (AD) and related dementias. Both disease-modifying and symptomatic agents will be considered.

The PACT RFP supports IND-enabling studies and early-phase clinical trials that test promising pharmacological interventions and devices for Alzheimer’s disease (AD) and related dementias. Both disease-modifying and symptomatic agents will be considered.

The Drug Development RFP seeks to support in vivo preclinical studies that advance lead molecules developed for Alzheimer’s disease and related dementias to IND-enabling studies. The proposed studies should be structured to deliver a compound with strong potential for clinical and commercial application.

The Drug Development RFP seeks to support in vivo preclinical studies that advance lead molecules developed for Alzheimer’s disease and related dementias to IND-enabling studies. The proposed studies should be structured to deliver a compound with strong potential for clinical and commercial application.

The Drug Development RFP seeks to support in vivo preclinical studies that advance lead molecules developed for Alzheimer’s disease and related dementias to IND-enabling studies. The proposed studies should be structured to deliver a compound with strong potential for clinical and commercial application.

This Notice informs potential applicants that the application types allowed in response to PAR-19-071 Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Not Allowed) have been expanded to include Revision and Resubmission applications. This change is effective as of the July 9, 2020 application due date.

This Notice informs potential applicants that the application types allowed in response to PAR-19-070 Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional) have been expanded to include Revision applications. This change is effective as of the July 9, 2020 application due date.

This Funding Opportunity Announcement (FOA) supports concerted efforts that take a multipronged, team-science strategy and apply high-throughput, genome-wide approaches to systematically discover and characterize functional genomic and epigenomic elements and elucidate and validate their functional roles and mechanisms of action underpinning the heterogeneity, pathogenesis, and progression of Alzheimer’s disease and related dementias (AD/ADRD).

The PαSS U19 seeks to understand and characterize the preclinical/prodromal phase of α-synucleinopathies. The study will recruit a cohort of iRBD subjects and follow them if/until they convert to PD, LBD, or MSA, using standardized psychometric tests, clinical/neurological evaluations, and diagnostic procedures. PαSS will identify changes associated with the earliest manifestations of α-synucleinopathy disease, including biomarkers of disease progression and potential surrogate endpoints. Biomarkers of α-synucleinopathy burden may range from neurophysiology, to changes in biofluid/tissue, to neuroimaging changes. The eventual goal is to find neuroprotective interventions for α-synucleinopathies.

The purpose of the NIH BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to enhance workforce diversity in the neuroscience workforce and maintain a strong cohort of new and talented, NIH-supported, independent investigators from diverse backgrounds in BRAIN Initiative research areas.

This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA RFA-NS-19-044 .

The purpose of the NIH BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to enhance workforce diversity in the neuroscience workforce and maintain a strong cohort of new and talented, NIH-supported, independent investigators from diverse backgrounds in BRAIN Initiative research areas.

This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to the companion FOA (RFA-NS-19-043)

The Jointly Sponsored NIH Predoctoral Training Program in the Neurosciences (JSPTPN) is an institutional program that supports broad and fundamental research training in the neurosciences. In addition to a broad education in the neurosciences, a key component will be a curriculum that provides a strong foundation in experimental design, statistical methodology and quantitative reasoning. JSPTPN programs are intended to be 2 years in duration and students may only be appointed to this training grant during the first 2 years of their graduate research training. The primary objective is to prepare students to be outstanding scientists equipped to pursue careers in neuroscience.

This FOA invites applications that propose to support advanced-stage development and utilization of novel research infrastructure to advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. This FOA will use the NIH Exploratory/Developmental Grants Phase II mechanism to provide support for expanded activities. Applicants are expected to have an existing research infrastructure developed, either through PA-12-064 or with other NIH or non-NIH support. Through this award, investigators will develop a mature and sustainable research infrastructure to support projects that address key interdisciplinary aging research questions.

This FOA invites applications that propose to develop novel research infrastructure that will advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. This FOA will use the NIH Phased Innovation Award (R21/R33) mechanism to provide up to 2 years of R21 support for initial developmental activities and up to 3 years of R33 support for expanded activities. Through this award, investigators will develop a sustainable research infrastructure to support projects that address key interdisciplinary aging research questions.

The Office of Research on Women's Health (ORWH) announces the availability of administrative supplements to support research highlighting the impact of sex and gender influences in human health and illness. Sex and gender are important considerations in many areas of research, including basic biological, psychological, social, and behavioral studies. With continuous interaction between sex and gender, human health is determined by both biology and expression of gender. The most robust experimental designs include consideration of both sex and gender; therefore, applications proposing to investigate the influence of both sex and gender factors are highly encouraged. The proposed research must address at least one objective from the five strategic goals of the 2019-2023 Trans-NIH Strategic Plan for Women's Health Research "Advancing Science for the Health of Women".

The Office of Research on Women's Health (ORWH) announces the availability of administrative supplements to support research highlighting health disparities among women in the US who are underrepresented, understudied, and underreported (U3) in biomedical research. The proposed research must address at least one objective from the strategic goals 1, 2, or 3 of the 2019-2023 Trans-NIH Strategic Plan for Women's Health Research "Advancing Science for the Health of Women."

NIA participates in NIH-wide programs to increase diversity in the research workforce. The goal of this FOA is to help outstanding postdoctoral researchers who are considered under-represented minority in science to transition into independent, tenure-track or equivalent faculty positions. NIA welcomes applications in all fields of aging research, including basic science, diseases and disabling conditions of aging, the social and behavioral consequences of an aging society, and topics in between. A particular priority of NIA at the moment is research on Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD).

This Funding Opportunity Announcement (FOA) invites R01 grant applications for funding health services research that improves the quality of care and patient outcomes during transitions of care. The purpose of this FOA is to support large-scale research projects that rigorously test promising interventions aimed at improving communication and coordination during care transitions.

This FOA is focused on three research areas of interest.

• Care transitions between primary care, acute care, and specialty providers
• Care transitions between different institutional care settings
• Care transitions with a focus on patients, their families and communities

The participating Institutes and Centers (ICs) are inviting applications to expand existing awards that are not currently focused on Alzheimer’s disease and its related dementias (AD/ADRD)—frontotemporal dementia, Lewy body dementia, vascular cognitive impairment with dementia, and multiple etiology dementias—to allow the research to develop such a focus. Active awards with project end dates in FY 2021 or later are eligible.

This FOA allows for applications that propose large-scale, complex research projects with multiple highly integrated components focused on a common research question relevant to aging. Such projects will likely involve an integrated multidisciplinary team of investigators within a single institution or a consortium of institutions.

This Small Research Grant Program (R03) will support important and innovative system biology projects in which more scientific insight is needed to improve the prevention, diagnosis, treatment, and care for individuals with Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). The overall goal of this R03 program is (i) to facilitate the next generation of researchers in the United States to pursue research and academic careers in neuroscience, AD/ADRD, and healthy brain aging and (ii) to stimulate established researchers who are not currently doing AD/ADRD research to perform pilot studies toward developing new, innovative AD/ADRD research programs that leverage and build upon their existing expertise.

This Small Research Grant (R03) will support important and innovative projects to provide needed scientific insight to improve the prevention, diagnosis, treatment, and/or care for individuals with Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). Specifically, this FOA will support archiving and leveraging existing data sets for analyses of projects covering a wide array of topics relating to AD/ADRD. The overall goal of this FOA is (i) to encourage the next generation of U.S. researchers to pursue research and academic careers in neuroscience, AD/ADRD, and healthy brain aging and (ii) to stimulate established researchers who are not currently doing AD/ADRD research to perform pilot studies developing new, innovative AD/ADRD research programs that leverage and build upon their existing expertise.

This Small Research Grant (R03) will support important and innovative projects focused on basic science approaches to elucidate neurodegenerative mechanisms/pathways of Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). Proposed projects should ultimately aim to improve the prevention, diagnosis, treatment, and/or care for individuals with AD/ADRD. The program seeks (i) to facilitate the next generation of researchers in the United States to pursue research and academic careers in neuroscience, AD/ADRD, and healthy brain aging and (ii) to stimulate established researchers who are not currently doing AD/ADRD research to perform pilot studies toward developing new, innovative AD/ADRD research programs that leverage and build upon their existing expertise.

The purpose of this Funding Opportunity Announcement (FOA) is to provide dissertation awards in all areas of research within NIA’s strategic priorities to increase the diversity of the scientific research workforce engaged in research on aging and aging-related health conditions.

The purpose of this award is to support outstanding scientific training of highly promising postdoctoral candidates with outstanding mentors. Candidates are eligible to apply for support from this program from ~12 months prior to the start of the proposed postdoctoral position to within 12 months after starting in the proposed postdoctoral position. This NINDS F32 seeks to foster early, goal-directed planning and to encourage applications for bold and/or innovative projects by the candidate that have the potential for significant impact. Inclusion of preliminary data is strongly discouraged; rather, this F32 seeks innovative research ideas and thoughtful plans for training and mentorship that will facilitate the development of the postdoctoral fellow into an outstanding scientist.

NIA is seeking applications from investigators looking to enhance their research programs to address selected NIH Alzheimer's Disease and Related Dementias Research Implementation Milestones. Investigators will be provided protected time to produce a program of investigation specific to selected goals/milestones. Investigators and their institutions will also be expected to advance more junior researchers' capacity to address selected goals/milestones.

The purpose of the NINDS Postdoctoral Mentored Career Development Award is to support the ability of outstanding, mentored postdoctoral researchers to develop a potentially impactful research project with a comprehensive career development plan that will enable them to launch an independent research program.

The purpose of this Funding Opportunity Announcement (FOA) is to support and accelerate human epigenomic investigations focused on identifying and characterizing the mechanisms by which social experiences at various stages in life, both positive and negative, affect gene function and thereby influence health trajectories or modify disease risk in racial/ethnic minority and other health disparity populations.

The purpose of the NINDS Postdoctoral Mentored Career Development Award is to support the ability of outstanding, mentored postdoctoral researchers to develop a potentially impactful research project with a comprehensive career development plan that will enable them to launch an independent research program.

National Institute on Alcohol Abuse and Alcoholism (NIAAA) in partnership with the National Institute on Aging (NIA) intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications to investigate mechanisms underlying the influence of alcohol on the onset and progression of Alzheimer’s disease and its related dementias.
This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and appropriate projects.

The FOA is expected to be published in Fall 2019 with an expected application due date in Spring 2020.

This FOA will utilize the R01 activity code. Details of the planned FOA are provided below.

The NETP Program Synergistic Idea Award supports new ideas that represent synergistic approaches to neurotoxin exposure and treatment-related Parkinson’s disease research involving two to four Principal Investigators (PIs) at the Assistant Professor (or equivalent) level or above. These investigators should utilize their complementary and synergistic perspectives to address a central problem or question in neurotoxin exposure and treatment-related Parkinson’s research. This award is designed to support both new and pre-existing partnerships and encourages participation of PIs from other research fields.

The NETP Program EIRA supports neurotoxin exposure and treatment-related Parkinson’s disease research opportunities for investigators in the early stages of their careers, under the guidance of a designated Mentor(s). The Early Investigator is considered the Principal Investigator (PI) of the application and must exhibit strong potential for, and commitment to, pursuing a career as an investigator at the forefront of Parkinson’s disease research; however, the PI is not required to have previous Parkinson’s disease research experience. Applications must include at least one Mentor, appropriate to the proposed research project, who has experience in Parkinson’s disease research and mentoring as demonstrated by a record of active funding, recent publications, and successful mentorship. The selected Mentor(s) should also demonstrate a clear commitment to the development of the PI toward independence as a neurotoxin exposure and treatment-related Parkinson’s disease researcher.

The NETP Program IIRA supports highly rigorous, multidisciplinary, high-impact research projects that have the potential to make an important contribution to neurotoxin exposure and treatment-related Parkinson’s research. This award mechanism supports the full spectrum of research from basic science through clinical research.

The National Institute of Neurological Disorders and Stroke (NINDS) intends to publish a Funding Opportunity Announcement (FOA) to solicit applications for the Morris K. Udall Centers of Excellence for Parkinson's Disease Research program. The overarching goal of this program is to establish a network of specialized Centers that work collaboratively as well as independently to define the causes of and discover improved treatments for Parkinson’s disease (PD). A more immediate goal for each Center is to rapidly advance synergistic, interdisciplinary research programs while serving as national leaders in PD research. Udall Centers also serve as local resources by providing research career enhancement activities for Center investigators and periodic outreach to the PD patient/advocacy community

Applicants to the Udall Centers program will identify and address an overall research theme that defines a critical challenge in PD research. The Center theme, proposed research projects, and associated cores will inform the etiology, pathogenesis or treatment of PD; investigations on related synucleinopathies may be included if such directly address the identified PD research challenge. Programmatic requirements of this FOA include: three or more Research Projects, including a dedicated Udall Catalyst project led by a junior investigator; an Administrative Core; at least one integrated Research Core that is essential to and accelerates the progress of two or more Research Projects; a mission statement for career enhancement of Center investigators, and a plan for periodic outreach to the local patient/advocacy community, including specific outreach events to convey Center research advances.

The goal of this program is to formalize new interdisciplinary teams to address critical gaps in PD research and establish a foundation of research discovery leading directly to an NINDS Morris K. Udall Center of Excellence for PD Research (P50) application.

Funds are available for administrative supplements to enhance the diversity of the research workforce by recruiting and supporting students, post-doctorates, and eligible investigators from underrepresented backgrounds, including those from groups that have been shown to be nationally underrepresented in health-related research. This supplement opportunity is also available to PD(s)/PI(s) of research grants who are or become disabled and need additional support to accommodate their disability in order to continue to work on the research project. Administrative supplements must support work within the scope of the original project.

This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.

The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate.

This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA.

The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate.

This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind.

This Notice of Special Interest (NOSI) is intended to promote behavioral and social research on the dementia care workforce and the impact on outcomes for persons living with Alzheimer's disease or Alzheimer's disease-related dementia (AD/ADRD) and their families. Broad areas of interest include (1) how economic and policy factors drive the composition and quality of the dementia care workforce; (2) demographic and familial factors that influence demand for and supply of dementia care workers; (3) training and certification effects on quality and retention of dementia care workers; and (4) the development of data resources required to study these issues.

This notice applies to due dates on or after July 9, 2020 and subsequent receipt dates through November 13, 2021.
Submit applications for the initiative using one of the following funding opportunity announcements (FOAs) or any reissue of these announcements through the expiration date of this notice.

PAR-19-070 Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)
PAR-19-071 Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for UG3/UH3 cooperative agreements to support the development of a publicly available core set(s) of COAs and their related endpoints for specific disease indications or for disease impacts that span multiple rare diseases of similar phenotypes.

The standard core set(s) can include different types of COAs (i.e. patient-reported outcome [PRO], clinician-reported outcome [ClinRO], observer-reported outcome [ObsRO], performance outcome [PerfO] instruments) and their related endpoints that assess a minimum list of impacts that matter most to patients, are likely to demonstrate change (including differences in trial arms related to disease burden, treatment burden, and if applicable, physical function) and should be reported in a clinical trial. A standard core set might be relevant across several disease populations or subgroups or be focused on attributes of a specific disease (a disease-specific or generic instrument that can adapted and applied more broadly across disease areas or across age groups).

The UG3/UH3 Phase Innovation Award Cooperative Agreement involves 2 phases. The UG3 phase will provide funding for 1 to 2 years to conduct planning activities. The UH3 phase will provide funding for 3 to 4 years to projects that successfully complete the planning activities and reach the projected milestones set in the UG3 phase.

This Notice of Special Interest (NOSI) underscores NIA’s continued commitment to research that seeks to better characterize the affective, cognitive, social, and motivational parameters of impaired and intact decision making in adults who are aging normally, as well as in individuals with mild cognitive impairment (MCI), Alzheimer’s disease (AD), and AD-related dementias (ADRD). Research is sought that characterizes the extent to which behavioral, psychological, and neural processes involved in decision making are differentially impacted in normal aging, MCI, and AD/ADRD. Investigations that target the influence of social factors on decision making or other factors that render older adults (with or without cognitive impairment) vulnerable to financial exploitation and other forms of mistreatment and abuse are of particular interest.

This NOSI also encourages preclinical and applied research on decision making that may facilitate the design of decision-supportive interventions for midlife and older adults with and without MCI and AD/ADRD. Specific opportunities include the development of decision-support interventions to leverage cognitive, emotional, social, and motivational strengths of these populations; tools to assess decisional capacities; strategies for simplifying choices and offering better defaults; and the promotion of timely adoption of optimal delegation practices (e.g., power of attorney, living wills, etc.). The use of animal models to explore the neural basis of affective, cognitive, social, and motivational parameters as they relate to age-related changes in decision making is also invited.

This Funding Opportunity Announcement (FOA) invites Exploratory Grant (P20) applications for the planning and initiation of collaborative efforts to advance Parkinson's Disease (PD) research. The goal of this program is to formalize new collaborative directions and/or novel interdisciplinary teams to address critical gaps in PD research and to establish a rigorous foundation of research discovery leading directly to an NINDS Morris K. Udall Center of Excellence (P50) application. Through this mechanism, the NINDS seeks to develop synergistic, proof-of-concept research efforts around investigator-defined gaps in PD research and support collaborative teams to develop a research plan, construct an effective administrative organization, create standardized policies/procedures, and gather rigorous preliminary data in support of novel ideas to address urgent needs and emergent issues in PD research. The Exploratory Grant theme and proposed research feasibility projects will inform the etiology, pathogenesis, or treatment of PD; investigations on related synucleinopathies may be included if such directly address the identified PD research gap.

This Funding Opportunity Announcement (FOA) invites applications for the Morris K. Udall Centers of Excellence for Parkinson’s Disease Research program. The overarching goal of this program is to support specialized research Centers that work collaboratively as well as independently to define the causes of and discover improved treatments for Parkinson’s disease (PD). A more immediate goal for each Center is to rapidly advance synergistic, interdisciplinary research programs while serving as national leaders in PD research. Applicants will identify an overall research theme that directly addresses a critical challenge in PD research. The Center theme, proposed research projects, and associated cores will inform the etiology, pathogenesis, or treatment of PD; investigations on related synucleinopathies may be included if such directly address the identified PD research challenge.

This FOA invites applications that employ integrative experimental and analytical approaches engaging basic and translational/clinical research aimed at developing a comprehensive understanding of the impact of sex differences on the trajectories of brain aging and disease, phenotypes of AD and AD-related dementias (ADRD) risk, individualized prevention, and responsiveness to pharmacologic and non-pharmacologic interventions.

To recognize the crucial role great mentors play in the development of future leaders in neuroscience, the National Institute of Neurological Disorders and Stroke (NINDS) created the Landis Award for Outstanding Membership. This award provides $100,000.00 (direct costs) to up to five (5) faculty members, who are considered to be outstanding mentors and trainers, to help foster the research career development of additional students and post-doctorates.

Nominations for the NINDS Landis Mentor Award will be accepted ONLY from current and former trainees of the nominated individual.

NIA invites outstanding graduate students from a wide range of broad research areas including, but not limited to, statistics, neuroscience, physics, immunology, microbiology, informatics, data sciences, psychology, (bio)behavioral science, anthropology, demography, sociology, social epidemiology, economics, public health, and engineering who are interested in receiving aging-related postdoctoral training to apply for this award.

The purpose of the Transition to Aging Research Award for Predoctoral Students is to increase, retain, and diversify the pool of trainees in aging and geriatric research.

The objective of the LRP-HDR is to recruit and retain highly qualified health professionals into research careers that focus on minority health disparities or other health disparities.

The NIH invites qualified health professionals who contractually agree to engage in NIH mission-relevant research for an average of at least 20 hours each week for at least two years, initially, to apply for an award in the Extramural LRP. The Extramural LRP repays up to $50,000 annually of a researcher's qualified educational debt in return for a commitment to engage in NIH mission-relevant research at a domestic, nonprofit, or government entity. Research funding from NIH is not required to participate in the Extramural LRP. LRP awards are based on an applicant's potential to build and sustain a research career.

The objective of the LRP-IDB is to recruit and retain highly qualified health professionals from disadvantaged backgrounds into clinical research careers. The emphasis on clinical research and individuals from disadvantaged backgrounds highlights the need for the involvement of a cadre of competent health professionals in clinical research.

The NIH invites qualified health professionals who contractually agree to engage in NIH mission-relevant research for an average of at least 20 hours each week for at least two years, initially, to apply for an award in the Extramural LRP. The Extramural LRP repays up to $50,000 annually of a researcher's qualified educational debt in return for a commitment to engage in NIH mission-relevant research at a domestic, nonprofit, or government entity. Research funding from NIH is not required to participate in the Extramural LRP. LRP awards are based on an applicant's potential to build and sustain a research career.

The objective of the LRP-CR is to recruit and retain highly qualified health professionals into biomedical or biobehavioral research careers.

The NIH invites qualified health professionals who contractually agree to engage in NIH mission-relevant research for an average of at least 20 hours each week for at least two years, initially, to apply for an award in the Extramural LRP. The Extramural LRP repays up to $50,000 annually of a researcher's qualified educational debt in return for a commitment to engage in NIH mission-relevant research at a domestic, nonprofit, or government entity. Research funding from NIH is not required to participate in the Extramural LRP. LRP awards are based on an applicant's potential to build and sustain a research career.